Cited by 640Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersNuclear Receptors and Signaling

The DOI matches its Crossref record; 238 of the 240 references it cites were found in a registry or an index.

Epidemiology of parkinson’s disease

Open access

Tanner, Caroline M., Goldman, Samuel M.·1996·Neurologic Clinics

DOI 10.1016/s0733-8619(05)70259-0PMC PMC7173037

Open this paper in CoChat — free account

Abstract

The epidemiologic studies reviewed here have provided insights into the etiology of PD. Evidence increasingly suggests that, like many other chronic age-related diseases, PD is a multifactorial disorder, with both genes and environment contributing to risk. As the elderly population of the world grows, incidence and prevalence of PD will continue to increase, underscoring the importance of further delineating risk factors. The introduction of levodopa and other pharmacologic therapies over the last 2 decades has postponed disease morbidity and mortality, but morbidity and mortality still are increased markedly relative to unaffected individuals. The development of therapies that may slow disease progression makes early identification and treatment of PD particularly important. Investigations of early markers of PD, or markers of disease susceptibility, are critical areas for future research. These efforts all will be aided by careful collaboration between epidemiologists and laboratory scientists.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0733-8619(05)70259-0

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
An Essay on the Shaking Palsy
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650
Case-Control Studies: Design, Conduct, Analysis.
Youkeles, L., & Schlesselman, J. J. (1983) · Journal of the American Statistical Association · doi:10.2307/2288156 · Cited by 2,358
Vitamin E Consumption and the Risk of Coronary Heart Disease in Men
Rimm, E. B., Stampfer, M. J., Ascherio, A., Giovannucci, E. L., Colditz, G. A., & Willett, W. C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282004 · Cited by 2,345
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Oxygen radicals and human disease
CROSS, C. E., HALLIWELL, B., BORISH, E. T., PRYOR, W. A., AMES, B. N., SAUL, R. L., McCORD, J. M., & HARMAN, D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-526 · Cited by 1,856
Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects
Nehlig, A., Daval, J., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,463

Show all 240 references

Research works printed but not linked: 13

Breteler, 1995, Risk factors for Parkinson's disease: A population-based case-control study, Neurology, 45, A214
Campanella, 1990, Etiology of Parkinson's disease: Results of two case-control studies, Mov Disord, 5, 31
Davanipour, 1990, Residential histories in Parkinson's disease patients, Ann Neurol, 28, 295
Goetz, 1990, Motor vehicle accident and Parkinson's disease disability, Mov Disord, 5, 16
Kurth, 1995, Lack of association of CYP2D6 and MAO-B alleles with Parkinson's disease in a Kansas cohort, Neurology, 45, A429
Mjones, 1949, Paralysis agitans: A clinical and genetic study, Acta Psychiatry and Neurology, 54, 1
Rocca, 1990, Prevalence of Parkinson's disease and other parkinsonisms: A door-to-door survey in two Sicilian communities, Neurology, 40, 422
Tanner, 1989, Dietary antioxidant vitamins and the risk of developing Parkinson's disease, Neurology, 39, 181
Tanner, 1988, Vitamin use and Parkinson's disease, Ann Neurol, 233, 182
Treves, 1990, Case-control study, with use of temporal approach, for evaluation of risk factors for Parkinson's disease, Mov Disord, 5, 11
Uitti, 1991, Parkinsonism survival in the Levodopa era, Neurology, 41, 190
Vierregge, 1991, Parkinson's disease in twins, Neurology, 41, 255
Zimmerman, 1991, Parkinson's disease in monozygotic twins: A followup, Neurology, 41, 255

Sorted by citations

Items 201–300 of 640

Sirtuin-2 Protects Neural Cells from Oxidative Stress and Is Elevated in Neurodegeneration
Singh, P., Hanson, P. S., & Morris, C. M. (2017) · Parkinson s Disease · doi:10.1155/2017/2643587 · Cited by 52
Small Extracellular Vesicles Secreted by Nigrostriatal Astrocytes Rescue Cell Death and Preserve Mitochondrial Function in Parkinson's Disease
Leggio, L., L'Episcopo, F., Magrì, A., Ulloa‐Navas, M. J., Paternò, G., Vivarelli, S., Bastos, C. A. P., Tirolo, C., Testa, N., Caniglia, S., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201203 · Cited by 54
Beyond the Microbiota: Understanding the Role of the Enteric Nervous System in Parkinson’s Disease from Mice to Human
Montanari, M., Imbriani, P., Bonsi, P., Martella, G., & Peppe, A. (2023) · Biomedicines · doi:10.3390/biomedicines11061560 · Cited by 51
Plants traditionally used in age-related brain disorders (dementia): an ethanopharmacological survey
Suganthy, N., Pandian, S. K., & Kasi, P. D. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2012.738423 · Cited by 53
Prevalence of Parkinson's disease and related disorders in the elderly population of greater Beijing, China
Zhang, Z., Anderson, D. W., Huang, J., Li, H., Hong, X., Wei, J., Yang, E., & Maraganore, D. M. (2003) · Movement Disorders · doi:10.1002/mds.10445 · Cited by 51
Perioperative Problems in Parkinson’s Disease and Their Management: Apomorphine with Rectal Domperidone
Gálvez-Jiménez, N., & Lang, A. E. (1996) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100038518 · Cited by 51
Role of Serum Cholesterol in Parkinson's Disease: A Meta-Analysis of Evidence
Gudala, K., Bansal, D., & Muthyala, H. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130196 · Cited by 50
Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
Ziemka‐Nałęcz, M., Jaworska, J., Sypecka, J., & Zalewska, T. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly073 · Cited by 53
Infection in childhood and neurological diseases in adult life
Martyn, C. N. (1997) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011603 · Cited by 50
Patient preferences and utilities for ‘off-time’ outcomes in the treatment of Parkinson's disease
Palmer, C. S., Schmier, J. K., Snyder, E. H., & Scott, B. L. (2000) · Quality of Life Research · doi:10.1023/a:1008903126315 · Cited by 50
The Consequences of GBA Deficiency in the Autophagy–Lysosome System in Parkinson’s Disease Associated with GBA
Pradas, E., & Martínez‐Vicente, M. (2023) · Cells · doi:10.3390/cells12010191 · Cited by 52
Younger age at onset of sporadic Parkinson’s disease among subjects occupationally exposed to metals and pesticides
Ratner, M. H., Farb, D. H., Ozer, J. S., Feldman, R. G., & Durso, R. (2014) · Interdisciplinary Toxicology · doi:10.2478/intox-2014-0017 · Cited by 49
Levodopa/carbidopa/entacapone in Parkinson’s disease
Seeberger, L., & Hauser, R. A. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.64 · Cited by 49
Genetic Epidemiology of Parkinson's Disease
Payami, H., & Zareparsi, S. (1998) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879801100207 · Cited by 49
The discovery and development of new potential antioxidant agents for the treatment of neurodegenerative diseases
Danta, C. C., & Piplani, P. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942218 · Cited by 48
Alanine-to-threonine substitutions and amyloid diseases: Butyrylcholinesterase as a case study
Podoly, E., Hanin, G., & Soreq, H. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.01.003 · Cited by 49
Voxelwise meta-analysis of gray matter anomalies in progressive supranuclear palsy and Parkinson's disease using anatomic likelihood estimation
Shao, N., Yang, J., Li, J., & Shang, H. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00063 · Cited by 45
Quantification of whole-body bradykinesia in Parkinson's disease participants using multiple inertial sensors
Memar, S., Delrobaei, M., Pieterman, M., McIsaac, K., & Jog, M. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.02.001 · Cited by 47
Parkinsonism: differential age‐trend in Helicobacter pylori antibody
Dobbs, S. M., Charlett, Dobbs, S. M., Weller, & Peterson, P. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00815.x · Cited by 47
Addressing the Linkage between Exposure to Pesticides and Human Health Effects—Research Trends and Priorities for Research
Ritter, L., Goushleff, N. C. I., Arbuckle, T. E., Cole, D. C., & Raizenne, M. E. (2006) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937400600755895 · Cited by 47
A role for viral infections in Parkinson’s etiology?
Olsen, L. K., Dowd, E., & McKernan, D. P. (2018) · Neuronal Signaling · doi:10.1042/ns20170166 · Cited by 48
Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson's disease
Korchounov, A., Schipper, H. I., Preobrazhenskaya, I. S., Kessler, K. R., & Yakhno, N. N. (2004) · Movement Disorders · doi:10.1002/mds.20061 · Cited by 46
Stem cell transplantation therapy in Parkinson’s disease
Fu, M., Li, C.-L., Lin, H.-L. H., Chen, P., Calkins, M. J., Chang, Y.-F., Cheng, P., & Yang, S. (2015) · SpringerPlus · doi:10.1186/s40064-015-1400-1 · Cited by 47
Acute complications of movement disorders surgery: Effects of age and comorbidities
Rughani, A. I., Hodaie, M., & Lozano, A. M. (2013) · Movement Disorders · doi:10.1002/mds.25610 · Cited by 45
MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions
Cunha, M. P., Pazini, F. L., Lieberknecht, V., Budni, J., Oliveira‐Giacomelli, Á., Rosa, J. M., Mancini, G., Mazzardo‐Martins, L., Colla, A. R. D. S., Leite, M. C., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0147-1 · Cited by 45
Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease
Henderson, M. X., Covell, D. J., Chung, C. H.-Y., Pitkin, R. M., Frasier, R. M., Decker, S. C., Riddle, D. M., Zhang, B., Gathagan, R. J., James, M. J., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104712 · Cited by 46
A Longitudinal Evaluation of Patients' Perceptions of Parkinson's Disease
Schenkman, M. L., Cutson, T. M., Zhu, C. W., & Whetten‐Goldstein, K. (2002) · The Gerontologist · doi:10.1093/geront/42.6.790 · Cited by 45
Prevalence of major neurological disorders among geriatric population in the metropolitan city of Kolkata.
Das, S. K., Biswas, A., Roy, J., Bose, P., Roy, T., Banerjee, T. K., Mukherjee, C. S., Raut, D. K., Chowdhury, A., & Hazra, A. (2008) · PubMed · Cited by 45
Dimeric structures of α-synuclein bind preferentially to lipid membranes
Giannakis, E., Pacífico, J., Smith, D. P., Hung, L. W., Masters, C. L., Cappai, R., Wade, J. D., & Barnham, K. J. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.01.012 · Cited by 45
“Prevalence rates of PD are ∼1% amongst individuals aged between 65–69 and increase in those aged 80 years and older to ∼3% [2].”
Background
Cost Effectiveness of Treatment of Parkinson??s Disease with Entacapone in the United States
Palmer, C. S., Nuijten, M. J. C., Schmier, J. K., Subedi, P., & Snyder, E. H. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220090-00005 · Cited by 45
Role of Polyphosphate in Amyloidogenic ProcessesPreprint
Lempart, J., & Jakob, U. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034041 · Cited by 44
“PD constitutes the Cite this article as Cold Spring Harb Perspect Biol 2019;11:a034041 7 second most common neurodegenerative disease affecting 1%–2% of the population above 60 years of age (Tanner and Goldman 1996).”
Background
Therapies modulating insulin resistance in Parkinson’s disease: A cross talk
Sharma, T., Kaur, D., Grewal, A. K., & Singh, T. G. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135754 · Cited by 44
Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of parkinson's disease
Najib, J. S. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80071-0 · Cited by 44
The Epidemiology of Parkinson's Disease
Chen, S.-Y., & Tsai, S. (2010) · Tzu Chi Medical Journal · doi:10.1016/s1016-3190(10)60044-4 · Cited by 44
Glaucoma: An Extension of Various Chronic Neurodegenerative Disorders
Jindal, V. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8416-8 · Cited by 45
The clinical spectrum of levodopa-induced motor complications
Hametner, E., Seppi, K., & Poewe, W. H. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5719-9 · Cited by 43
“It is the second most common neurodegenerative disorder in the elderly, with incidence and prevalence rates increasing with age [7, 52, 63].”
Background
The Synapse as a Central Target for Neurodevelopmental Susceptibility to Pesticides
Vester, A. I., & Caudle, W. M. (2016) · Toxics · doi:10.3390/toxics4030018 · Cited by 45
Rationally Designed Variants of α-Synuclein Illuminate Its in vivo Structural Properties in Health and Disease
Dettmer, U. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00623 · Cited by 43
Automated assessment of Parkinsonian finger-tapping tests through a vision-based fine-grained classification model
Li, H., Shao, X., Zhang, C., & Qian, X. (2021) · Neurocomputing · doi:10.1016/j.neucom.2021.02.011 · Cited by 43
Impairment, disability, and life satisfaction in Parkinson's disease
Dural, A., Atay, M. B., Akbostancı, M. C., & Küçükdeveci, A. A. (2003) · Disability and Rehabilitation · doi:10.1080/0963828021000043761 · Cited by 44
Exclusion of Elderly Subjects From Clinical Trials for Parkinson Disease
Mitchell, S. L., Sullivan, E., & Lipsitz, L. A. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550230060018 · Cited by 43
Prevalence of Parkinson’s disease in Korea
Seo, W., Koh, S., Kim, B., Yu, S.-W., Park, M.-H., Park, K. W., & Lee, D.-H. (2007) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2006.09.005 · Cited by 42
CYP2D6 phenotypes and Parkinson's disease risk: A meta-analysis
Lu, Y., Peng, Q., Zeng, Z., Wang, J., Deng, Y., Xie, L., Mo, C., Zeng, J., Qin, X. Y., & Li, S. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.10.030 · Cited by 42
Activation of Transcription Factor MEF2D by Bis(3)-cognitin Protects Dopaminergic Neurons and Ameliorates Parkinsonian Motor Defects
Yao, L., Li, W., She, H., Dou, J., Jia, L., He, Y., Yang, Q., Zhu, J., Cápiro, N. L., Walker, D. I., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.367540 · Cited by 41
The Relationship Between Speech Production and Speech Perception Deficits in Parkinson's Disease
Keyser, K. D., Santens, P., Bockstael, A., Botteldooren, D. B., Talsma, D., Vos, S. D., Cauwenberghe, M. V., Verheugen, F., Corthals, P., & Letter, M. D. (2016) · Journal of Speech Language and Hearing Research · doi:10.1044/2016_jslhr-s-15-0197 · Cited by 49
Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta
Boyd, J. D., Jang, H., Shepherd, K. R., Faherty, C. J., Slack, S. D., Jiao, Y., & Smeyne, R. J. (2007) · Brain Research · doi:10.1016/j.brainres.2007.07.067 · Cited by 40
Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug
D’Aurizio, E., van Nostrum, C. F., van Steenbergen, M. J., Sozio, P., Siepmann, F., Siepmann, J., Hennink, W. E., & Stefano, A. D. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.02.036 · Cited by 40
Psychiatric diseases predated the occurrence of Parkinson disease: a retrospective cohort study
Lin, H., Lin, H., & Chen, Y. (2014) · Annals of Epidemiology · doi:10.1016/j.annepidem.2013.12.010 · Cited by 40
Neuroprotective Effect ofCoptis chinensisin MPP+ and MPTP-Induced Parkinson’s Disease Models
Friedemann, T., Ying, Y., Wang, W., Kramer, E. R., Schumacher, U., Fei, J., & Schröder, S. (2016) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x16500506 · Cited by 40
Organoid and pluripotent stem cells in Parkinson’s disease modeling: an expert view on their value to drug discovery
Marotta, N., Kim, S., & Krainc, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1703671 · Cited by 40
“5 to 1 percent in people 65 to 69 years of age rising sharply to 1 to 3 percent in people over 80 years of age [173,174].”
Background
Rotigotine Transdermal Patch
Baldwin, C. M., & Keating, G. M. (2007) · CNS Drugs · doi:10.2165/00023210-200721120-00007 · Cited by 40
Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: A Markov Process Analysis
Nuijten, M. J. C., van Iperen, P., Palmer, C., van Hilten, B. J., & Snyder, E. (2001) · Value in Health · doi:10.1046/j.1524-4733.2001.004004316.x · Cited by 39
The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice
Shepherd, K. R., Lee, E.-S., Schmued, L. C., Jiao, Y., Ali, S. F., Oriaku, E. T., Lamango, N. S., Soliman, K. F. A., & Charlton, C. G. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.02.013 · Cited by 38
Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites
Stroupe, K. T., Weaver, F., Cao, L., Ippolito, D., Barton, B., Burnett-Zeigler, I. E., Holloway, R., Vickrey, B., Simuni, T., & Follett, K. (2014) · Movement Disorders · doi:10.1002/mds.26029 · Cited by 37
Diagnosing Parkinson Disease
Hess, C. W., & Okun, M. S. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000345 · Cited by 40
Dopaminergic drugs and the risk of hip or femur fracture: a population-based case–control study
Arbouw, M. E. L., Movig, K. L. L., van Staa, T. P., Egberts, T. C. G., Souverein, P. C., & de Vries, F. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1455-3 · Cited by 40
Attenuation of Paraquat-Induced Dopaminergic Toxicity on the Substantia Nigra by (−)-Deprenyl in Vivo
Liou, H., Chen, R.-C., Chen, T. H.-H., Tsai, Y., & Tsai, M.-C. (2001) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2001.9130 · Cited by 38
Chemical profiling of cerebrospinal fluid by multiple reaction monitoring mass spectrometry
Ferreira, C. R., Yannell, K. E., Mollenhauer, B., Espy, R. D., Cordeiro, F. B., Ouyang, Z., & Cooks, R. G. (2016) · The Analyst · doi:10.1039/c6an01618a · Cited by 37
Istradefylline for the treatment of Parkinson's disease
Park, A., & Stacy, M. A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.643869 · Cited by 36
Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers
Sayad, M., Zouambia, M., Chaouch, M., Ferrat, F., Nebbal, M., Bendini, M., Lesage, S., Brice, A., Errahmani, M. B., & Asselah, B. (2016) · BMC Neuroscience · doi:10.1186/s12868-016-0240-4 · Cited by 36
The PPARGC1A locus and CNS-specific PGC-1α isoforms are associated with Parkinson's Disease
Soyal, S. M., Zara, G., Ferger, B., Felder, T. K., Kwik, M., Nofziger, C., Dossena, S., Schwienbacher, C., Hicks, A. A., Pramstaller, P. P., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.016 · Cited by 36
“As PD risk increases with age, the incidence of this devastating and debilitating condition is predicted to have increased a further 50% by 2030 (Dorsey et al., 2007; Tanner and Goldman, 1996).”
Restorative Neurosurgery: Opportunities for Restoration of Function in Acquired, Degenerative, and Idiopathic Neurological Diseases
Thompson, T. P., Lunsford, L. D., & Kondziolka, D. S. (1999) · Neurosurgery · doi:10.1097/00006123-199910000-00001 · Cited by 36
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases
H. Swerdlow, R. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072535 · Cited by 35
Greater Loss of White Matter Integrity in Postural Instability and Gait Difficulty Subtype of Parkinson's Disease
Gu, Q., Huang, P., Xuan, M., Xu, X., Li, D., Sun, J., Yu, H., Wang, C., Luo, W. F., & Zhang, M. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2014.34 · Cited by 35
Deep Learning for Detecting Freezing of Gait Episodes in Parkinson’s Disease Based on Accelerometers
Camps, J., Samà, A., Martín, M., Rodríguez-Martín, D., Pérez‐López, C., Alcaine, S., Mestre, B., Prats, A., Crespo, M. C., Cabestany, J., et al. (2017) · Lecture notes in computer science · doi:10.1007/978-3-319-59147-6_30 · Cited by 35
The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson’s Disease
Zhao, Y., Qiong-Zhang, Zhang, J., Lou, Z., Zu, H.-B., Wang, Z., Wei-cheng, Z., Kai-Yao, & Xiao, B. (2018) · Aging and Disease · doi:10.14336/ad.2017.1028 · Cited by 35
“The prevalence of Parkinson’s disease (PD) increases with increasing age [2, 3].”
Background
Does Mitochondrial DNA Play a Role in Parkinson's Disease? A Review of Cybrid and Other Supportive Evidence
Swerdlow, R. H. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.3948 · Cited by 35
The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain
García-Ramos, R., Valdés, E. L., Ballesteros, L., Jesús, S., & Mir, P. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2013.04.008 · Cited by 34
A Cleaning Crew: The Pursuit of Autophagy in Parkinson’s Disease
Parekh, P., Sharma, N., Gadepalli, A., Shahane, A., Sharma, M., & Khairnar, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00244 · Cited by 34
Incidence and prevalence of Parkinson’s disease in Buenos Aires City, Argentina
Bauso, D., Tartari, J. P., Stefani, C., Rojas, J. I., Giunta, D. H., & Cristiano, E. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03683.x · Cited by 34
Bursting activity of substantia nigra pars reticulata neurons in mouse parkinsonism in awake and anesthetized states
Lobb, C. J., & Jaeger, D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.12.026 · Cited by 33
Exon Arrays Reveal Alternative Splicing Aberrations in Parkinson’s Disease Leukocytes
Soreq, L., Bergman, H., Israel, Z. H., & Soreq, H. (2011) · Neurodegenerative Diseases · doi:10.1159/000332598 · Cited by 34
Prevalence of movement disorders in an elderly nursing home population
Tse, W., Libow, L. S., Neufeld, R. R., Lesser, G. T., Frank, J. S., Dolan, S., Tarshish, C. Y., Graciès, J., Olanow, C. W., Koller, W. C., et al. (2007) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2007.05.008 · Cited by 34
Environmental factors and Parkinson's disease: a case–control study in the Tuscany region of Italy
Nuti, A., Ceravolo, R., Dell’Agnello, G., Gambaccini, G., Bellini, G., Kiferle, L., Rossi, C. A., Logi, C., & Bonuccelli, U. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.008 · Cited by 34
“To date the aetiology of Parkinson’s disease (PD) is unknown although both genetic susceptibility and environmental factors appear to play an important role in the development of the disease [1].”
Background
IGF-1 protects SH-SY5Y cells against MPP+-induced apoptosis via PI3K/PDK-1/Akt pathway
Kim, C., & Park, S. (2018) · Endocrine Connections · doi:10.1530/ec-17-0350 · Cited by 33
Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy
Leriche, L., Björklund, T., Breysse, N., Besret, L., Grégoire, M., Carlsson, T., Dollé, F., Mandel, R. J., Déglon, N., Hantraye, P., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4491-08.2009 · Cited by 33
Multiple Protective Roles of Nanoliposome‐Incorporated Baicalein against Alpha‐Synuclein Aggregates
Aliakbari, F., Mohammad‐Beigi, H., Abbasi, S., Rezaei‐Ghaleh, N., Lermyte, F., Parsafar, S., Becker, S., Tafreshi, A. P., O’Connor, P. B., Collingwood, J. F., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202007765 · Cited by 32
Mechanistic Insights, Treatment Paradigms, and Clinical Progress in Neurological Disorders: Current and Future Prospects
Alkahtani, S. H., AL–Johani, N. S., & Alarifi, S. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021340 · Cited by 36
A novel therapeutic approach to 6-OHDA-induced Parkinson’s disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase
Wu, S. P., Fu, A. L., Wang, Y. X., Yu, L., Jia, P. Y., Li, Q., Jin, G. Z., & Sun, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.247 · Cited by 32
Advances in NURR1-Regulated Neuroinflammation Associated with Parkinson’s Disease
Al‐Nusaif, M., Lin, Y., Li, T., Cheng, C., & Le, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416184 · Cited by 32
“5–1% among people aged 60–69 and rising to 1–3% over the age of 80 [2,3].”
Background
Discrimination between healthy and patients with Parkinson’s disease from hand resting activity using inertial measurement unit
Peres, L. B., Calil, B. C., da Silva, A. P. S. P. B., Dionísio, V. C., Vieira, M. F., Andrade, A. D. O., & Pereira, A. A. (2021) · BioMedical Engineering OnLine · doi:10.1186/s12938-021-00888-2 · Cited by 32
REVIEW OF NATURAL PRODUCTS ON PARKINSON’S DISEASE PATHOLOGY
Essa, M. M., Braidy, N., Bridge, W. J., Subash, S., Manivasagam, T., Vijayan, R. K., Al‐Adawi, S., & Guillemin, G. J. (2014) · Journal of Aging Research and Lifestyle · doi:10.14283/jarcp.2014.23 · Cited by 31
The prevalence of Parkinson’s disease in a rural area of North-East England
Walker, R. W., Hand, A., Jones, C., Wood, B. H., & Gray, W. K. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.07.002 · Cited by 31
Parkinson's disease
Siderowf, A. D. (2001) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70035-9 · Cited by 31
Destabilization of survival factor MEF2D mRNA by neurotoxin in models of Parkinson's disease
Wang, B., Cai, Z., Lu, F., Li, C., Zhu, X., Su, L., Gao, G., & Yang, Q. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12765 · Cited by 30
“The disease is characterized pathologically by the loss of pigmented dopaminergic (DA) neurons in the substantial nigra pars compacta (SNc) (Tanner and Goldman 1996; Tatton and Kish 1997; de Lau and Breteler 2006).”
Background
Possible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disorders
Lakkappa, N., Krishnamurthy, P. T., Hammock, B. D., Velmurugan, D., & Bharath, M. M. S. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.06.003 · Cited by 30
Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease
Marrone, L., Bus, C., Schöndorf, D. C., Fitzgerald, J. C., Kübler, M., Schmid, B., Reinhardt, P., Reinhardt, L., Deleidi, M., Levin, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192497 · Cited by 30
Biophysical Characterization of α-Synuclein and Rotenone Interaction
Silva, B., Einarsdóttir, Ó., Fink, A. L., & Uversky, V. N. (2013) · Biomolecules · doi:10.3390/biom3030703 · Cited by 30
Clinical profile of parkinsonian disorders in the tropics: Experience at Kano, northwestern Nigeria
Femi, O. L., Ibrahim, A., & Aliyu, S. (2012) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.102589 · Cited by 30
Parkinson’s disease, CYP2D6 polymorphism, and age
Payami, H., Lee, N., Zareparsi, S., McNeal, M. G., Camicioli, R. M., Bird, T. D., Sexton, G. J., Gancher, S., Kaye, J. A., Calhoun, D., et al. (2001) · Neurology · doi:10.1212/wnl.56.10.1363 · Cited by 30
Using Liquid Levodopa in the Treatment of Parkinson??s Disease
Kurth, M. (1997) · Drugs & Aging · doi:10.2165/00002512-199710050-00002 · Cited by 30
Age-related decline in the responsiveness of motor cortex to plastic forces reverses with levodopa or cerebellar stimulation
Kishore, A., Popa, T., James, P., Yahia‐Cherif, L., Backer, F., Chacko, L. V., Govind, P., Pradeep, S., & Meunier, S. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.004 · Cited by 30
“, 2009), and an increased probability of developing Parkinson’s disease, the archetypal movement disorder (Tanner and Goldman, 1996).”
Background
Species fractionation in a case-control study concerning Parkinson’s disease: Cu-amino acids discriminate CSF of PD from controls
Willkommen, D., Lucio, M., Schmitt‐Kopplin, P., Gazzaz, M., Schroeter, M., Sigaroudi, A., & Michalke, B. (2018) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2018.01.005 · Cited by 31
Neuroprotective and Neurogenic Effects of Novel Tetramethylpyrazine Derivative T-006 in Parkinson's Disease Models Through Activating the MEF2-PGC1α and BDNF/CREB Pathways
Chen, H., Cao, J., Zha, L., Wang, P., Liu, Z., Guo, B., Zhang, G., Sun, Y., Zhang, Z., & Wang, Y. (2019) · Aging · doi:10.18632/aging.103551 · Cited by 29
Subthalamic Nucleus Deep Brain Stimulation Impacts Language in Early Parkinson's Disease
Phillips, L. L., Litcofsky, K. A., Pelster, M. W., Gelfand, M. P., Ullman, M. T., & Charles, D. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042829 · Cited by 29
The perioperative management of Parkinson's disease revisited
Gálvez-Jiménez, N., & Lang, A. E. (2004) · Neurologic Clinics · doi:10.1016/j.ncl.2004.01.004 · Cited by 29
“It has been estimated that PD has a prevalence of 59 to 187 per 100,000 population worldwide [1] with an annual incidence of 20 per 10,000 [2,3], and in North America 1% of the population over age 60 is affected by the disease [1,3,4].”
Background
Prevalence of Parkinsonism and Parkinson's disease in Qena governorate/Egypt: a cross-sectional community-based survey
Khedr, E. M., Fawi, G., Abbas, M. A. A., Mohammed, T. A., Elfetoh, N. A., Al-Attar, G. S. T., & Zaki, A. F. (2015) · Neurological Research · doi:10.1179/1743132815y.0000000020 · Cited by 29
Parkinson's Disease in the Gulf Countries: An Updated Review
Alamri, Y., MacAskill, M. R., Anderson, T., & Benamer, H. T. S. (2015) · European Neurology · doi:10.1159/000442283 · Cited by 29
PINK1 deficiency enhances autophagy and mitophagy induction
Gómez‐Sánchez, R., Yakhine-Diop, S. M. S., Pedro, J. M. B., Pizarro‐Estrella, E., Rodríguez‐Arribas, M., Climent, V. E., Martín‐Cano, F. E., González-Soltero, M. E., Tandon, A., Fuentes, J. M., et al. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1046579 · Cited by 30
Racial Differences in Parkinson’s Disease Medication Use in the Reasons for Geographic and Racial Differences in Stroke Cohort: A Cross-Sectional Study
Yacoubian, T. A., Howard, G., D, B. M. K. M., Sands, C. D., & Standaert, D. G. (2009) · Neuroepidemiology · doi:10.1159/000254568 · Cited by 29

Authors: Tanner, C. M., & Goldman, S. M.
Affiliations: Parkinson's Institute and Clinical Center (US)
ORCID: Tanner, Caroline M.
Goldman, Samuel M.
Venue: Neurologic Clinics
Publisher: Elsevier BV
Published: 1996-05
Volume: 14
Issue: 2
Pages: 317-335
ISSN: 0733-8619 (ISSN-L)
DOI: 10.1016/s0733-8619(05)70259-0
PMC: PMC7173037
OpenAlex: W2084553926
Semantic Scholar: 722f96a983f226977773068a6a70c00979c0cbd5
Cited by: 640
References: 240
Citations by year: 2026: 9 · 2025: 10 · 2024: 17 · 2023: 29 · 2022: 23 · 2021: 26 · 2020: 14 · 2019: 24 · 2018: 35 · 2017: 36 · 2016: 28 · 2015: 26 · 2014: 32 · 2013: 28 · 2012: 19
FWCI: 11.14
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neurologic Clinics (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA094089)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, etiology, complex diseases, genetic risk factors, environmental risk factors, incidence, prevalence, levodopa, early markers, disease susceptibility, disease progression
MeSH terms: Aged, Consanguinity, Diet, Environmental Exposure, Female, Humans, Male, Middle Aged, Parkinson Disease, Risk Factors, Smoking, Global Health, Hazardous Substances, Incidence, Prevalence, Age Distribution, Sex Distribution, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of parkinson’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks